j
kevin
baird
erni
j
nelwan
w
robert
taylor
malaria
often
occur
return
travel
peopl
visit
friend
rel
malariaendem
area
acut
malaria
speci
medic
emerg
febril
ill
patient
return
travel
malariaendem
area
presum
malaria
proven
otherwis
five
speci
plasmodi
parasit
infect
human
caus
essenti
similar
febril
ill
uncompl
malaria
resembl
mani
infect
diagnosi
requir
laboratori
confirm
uncompl
malaria
may
progress
sever
multisystem
lifethreaten
diseas
within
hour
diagnos
treat
promptli
sever
chemotherapeut
option
exist
treat
uncompl
malaria
guid
parasit
speci
local
drug
resist
pattern
artemisininbas
combin
potent
antimalari
drug
sever
complic
malaria
intraven
intramuscular
artesun
first
line
treatment
patient
includ
trimest
pregnant
women
plasmodium
vivax
plasmodium
oval
relaps
malaria
requir
radic
cure
primaquin
malaria
travel
pose
highli
complex
potenti
danger
clinic
challeng
five
speci
plasmodi
parasit
routin
infect
human
may
progress
complic
sever
diseas
promptli
diagnos
effect
treat
notion
malign
benign
speci
plasmodia
consid
danger
fallaci
manag
patient
malaria
requir
navig
mani
diagnost
therapeut
option
potenti
pitfal
chapter
guid
approach
patient
may
malaria
success
manag
confirm
malaria
chapter
set
asid
manag
patient
resid
endem
area
focus
travel
patient
popul
endem
malaria
occur
global
across
tropic
subtrop
countri
even
temper
korean
peninsula
thousand
travel
year
diagnos
acut
malaria
treat
surviv
data
nonendem
countri
show
mean
number
import
case
per
year
nearli
led
franc
unit
kingdom
unit
state
plasmodium
falciparum
predomin
speci
africa
especi
western
africa
p
vivax
common
eastern
africa
asia
america
p
vivax
common
case
fatal
rate
cfr
import
sever
malaria
typic
rang
death
gener
occur
among
take
antimalari
chemoprophylaxi
face
delay
diagnosi
treatment
geograph
isolationtravel
reluct
seek
medic
attent
misdiagnosi
inappropri
ineffect
therapi
promptli
diagnos
treat
uncompl
malaria
rare
progress
lifethreaten
sever
malaria
malaria
one
diseas
number
diseas
except
rare
instanc
congenit
transfusiontranspl
malaria
malaria
acquir
bite
particular
speci
mosquito
genu
anophel
carri
five
speci
sporozoan
parasit
genu
plasmodium
known
routin
infect
human
tabl
speci
typic
caus
undifferenti
febril
ill
character
period
fever
chill
headach
muscl
ach
malais
sometim
nausea
vomit
symptom
essenti
across
five
speci
discrimin
valu
speci
may
also
progress
sever
complic
system
ill
p
falciparum
may
often
greater
rapid
compris
cerebr
pulmonari
renal
hepat
circulatori
dysfunct
although
speci
specif
domin
syndrom
tend
vari
speci
age
patient
see
tabl
speci
clinic
present
thu
repres
particular
malaria
given
appropri
term
eg
acut
uncompl
oval
malaria
sever
vivax
malaria
global
descript
unwel
patient
cerebr
malaria
due
p
falciparum
p
knowlesiinduc
acut
respiratori
distress
syndrom
ard
therefor
clinician
make
speci
diagnosi
defin
ill
understand
vulner
patient
inform
clinic
manag
malaria
travel
differ
import
way
local
resid
chronic
expos
malaria
vari
degre
natur
acquir
immun
heavili
endem
area
risk
sever
complic
falciparum
malaria
sharpli
declin
age
nearli
billion
peopl
live
risk
malaria
across
tropic
subtrop
even
temper
zone
million
visit
area
year
thousand
appear
hospit
posttravel
acut
malaria
diagnosi
manag
medic
emerg
ill
may
deterior
rapidli
without
prompt
diagnosi
effect
treatment
among
five
speci
plasmodium
respons
human
malaria
plasmodium
falciparum
often
deterior
rapidli
speci
potenti
threaten
life
malign
benign
speci
malaria
parasit
danger
fallaci
clinic
malaria
mimic
common
tropic
infect
diagnosi
requir
laboratori
confirm
malarialik
symptom
patient
expos
risk
presum
malaria
proven
otherwis
intraven
intramuscular
artesun
use
sever
malaria
speci
patient
includ
trimest
pregnanc
primaquin
administ
vivax
oval
malaria
affirm
dehydrogenas
normal
statu
respons
delay
attack
late
falciparum
attack
may
also
occur
quit
rare
fever
occur
almost
patient
often
preced
short
prodrom
day
vagu
abdomin
discomfort
headach
muscl
ach
malais
cough
surprisingli
common
children
may
letharg
anorex
irrit
hand
third
patient
confirm
malaria
may
present
afebril
due
cyclic
natur
paroxysm
link
asexu
reproduct
cycl
parasit
blood
fever
classic
descript
cycl
hour
accord
speci
see
tabl
rare
appear
nonimmun
patient
daili
paroxysm
rule
regardless
infect
speci
paroxysm
may
begin
late
afternoon
intract
vomit
follow
chill
profound
shiver
last
hour
pass
quickli
progress
spike
fever
drench
sweat
sever
hour
defervesc
earli
morn
leav
patient
exhaust
final
abl
sleep
wherea
risk
nonimmun
patient
sharpli
increas
age
anoth
exampl
sever
anemia
appear
commonli
endem
area
hospit
malaria
appear
much
less
often
travel
diagnosi
chapter
set
asid
complex
consid
nonimmun
travel
onset
symptom
uncompl
malaria
nonimmun
patient
take
chemoprophylaxi
typic
within
day
infecti
anophelin
mosquito
bite
travel
diagnos
falciparum
malaria
clinic
attack
occur
within
month
travel
cessat
suppress
chemoprophylaxi
vivax
malaria
hand
appear
month
later
suppress
chemoprophylaxi
impact
latent
liver
stage
hypnozoit
one
report
chloroquin
resist
southern
sumatra
indonesia
differenti
diagnosi
acut
undifferenti
fever
travel
broad
good
histori
import
obtain
clue
exposur
malaria
infect
often
may
occur
knowledg
incub
period
help
rule
certain
ill
thorough
physic
examin
mandatori
malaria
mani
manifest
present
clinic
pictur
may
one
domin
symptom
sign
favor
diagnos
influenzalik
ill
gastroenter
pneumonia
enceph
hepat
moreov
number
pathogen
mimic
malaria
also
broad
tabl
key
resolv
diagnost
challeng
laboratori
confirm
malaria
quickli
possibl
see
upcom
discuss
diagnosi
may
rule
three
consecut
malaria
blood
film
prefer
conjunct
rapid
test
examin
interv
neg
within
hour
malaria
caus
third
import
fever
coinfect
anoth
pathogen
suspect
patient
remain
febril
despit
effect
antimalari
treatment
thwait
day
offer
exhaust
review
caus
import
fever
presumpt
clinic
diagnosi
malaria
may
made
high
probabl
recent
exposur
infect
abil
confirm
diagnosi
laboratori
examin
within
hour
treatment
await
delay
confirm
malaria
emerg
like
differenti
recoveri
within
hour
physic
sign
uncompl
malaria
nonspecif
includ
fever
almost
alway
ill
cours
splenomegali
hepatomegali
jaundic
hematolog
find
noteworthi
proport
patient
degre
thrombocytopenia
ii
platelet
count
iii
total
white
cell
count
wcc
normal
rang
iv
similar
rate
leukopenia
leukocytosi
v
anemia
hemoglobin
hbc
gdl
wcc
differenti
present
variabl
eg
eosinopenia
lymphopenia
neutrophilia
atyp
lymphocyt
never
use
rule
malaria
liver
enzym
aspart
transaminasealanin
transaminas
astalt
rais
patient
total
bilirubin
rais
lactat
dehydrogenas
ldh
liver
red
cell
origin
report
patient
mani
import
tropic
infect
share
laboratori
abnorm
patient
present
sever
malaria
clearli
unwel
may
exhibit
symptom
sign
system
ill
clinic
indistinguish
condit
sepsi
septic
shock
world
health
organ
definit
sever
malaria
criteria
adult
children
base
mostli
data
malariaendem
countri
tabl
one
european
seri
patient
import
sever
malaria
criteria
main
featur
seen
hyperparasitemia
ii
jaundic
iii
impair
consciousnesscoma
iv
acut
kidney
injuri
v
shock
vi
respiratori
failureard
vii
spontan
bleed
viii
acidosi
ix
hypoglycemia
x
multipl
convuls
median
number
criteria
patient
underli
comorbid
data
broadli
consist
earlier
seri
patient
report
bruneel
et
al
highlight
contribut
microscopyfew
mani
avail
kit
detect
parasitemia
lower
sensit
p
vivax
malaria
typic
kit
reveal
parasit
count
stage
present
rapid
test
design
detect
p
falciparum
histidinerich
protein
neg
speci
includ
p
knowlesi
nonp
falciparum
malaria
detect
rapid
test
contain
pan
antigen
strip
tend
less
sensit
problem
strain
p
falciparum
wild
delet
hrp
gene
render
undetect
hrpbase
rapid
diagnost
test
rdt
wide
varieti
polymeras
chain
reaction
pcr
test
malaria
describ
sensit
one
parasit
per
microlit
may
speci
specif
quantit
test
reveal
parasit
load
examin
tissu
pcr
test
far
sensit
mix
speci
infect
even
expert
microscopi
princip
drawback
high
level
laboratori
expertis
cost
time
requir
laboratori
special
reagent
hand
typic
requir
least
sever
hour
often
entir
workday
report
find
pcr
diagnosi
thu
typic
confirm
earli
diagnosi
guid
immedi
therapi
sever
option
exist
treat
malaria
tabl
choic
depend
drug
avail
parasit
speci
local
resist
pattern
power
antimalari
drug
artemisininbas
combin
act
act
unavail
nonendem
countri
chloroquin
cq
use
commonli
treat
p
vivax
p
malaria
p
oval
p
knowlesi
howev
cqresist
p
vivax
well
document
southeast
asia
indonesian
archipelago
papua
new
guinea
report
foci
rang
countri
doubt
use
act
although
cq
effect
uncompl
p
knowlesi
act
rapidli
act
prefer
infect
tendenc
produc
rapidli
sever
diseas
atovaquon
proguanil
avail
wide
retain
efficaci
p
falciparum
failur
report
western
cambodia
p
vivax
p
knowlesi
individu
take
chemoprophylaxi
typic
doxycyclin
atovaquon
proguanil
mefloquin
treatment
exclud
drug
initi
effect
antimalari
treatment
would
consist
clinic
diagnosi
malaria
confirm
nonetheless
requir
laboratori
evid
microscop
diagnosi
acut
ill
patient
plasmodi
parasit
may
observ
stain
thick
blood
film
examin
oil
immers
light
microscopi
technician
certifi
compet
access
goodqual
reagent
microscop
thin
film
use
quantifi
hyperparasitemia
aid
identif
speci
rather
search
parasit
guidanc
endem
laboratori
typic
demand
examin
least
ocular
field
declar
slide
neg
malaria
nonendem
clinic
see
nonimmun
patient
search
much
extens
eg
field
mani
nonimmun
patient
far
lower
threshold
parasitemia
acut
febril
ill
often
possibl
microscopist
decid
upon
speci
observ
employ
varieti
visual
clue
bananashap
gametocyt
p
falciparum
pathognomon
exampl
enlarg
infect
red
blood
cell
contain
ameboid
parasit
point
p
vivax
p
oval
matur
schizont
may
seen
offer
strong
clue
speci
ident
howev
microscopist
also
face
limit
regard
young
ring
form
observ
specif
diagnosi
may
possibl
patient
infect
p
knowlesi
microscop
diagnosi
virtual
impossibleit
often
mistaken
p
malaria
speci
characterist
present
low
parasitemia
rather
frequent
occur
hyperparasitemia
p
knowlesi
malaria
patient
malaria
clinic
threat
correl
densiti
parasitemia
proven
p
falciparum
p
knowlesi
malaria
blood
respect
associ
increas
risk
sever
diseas
howev
much
less
clear
patient
p
vivax
malaria
biomass
may
sequest
spleen
marrow
level
parasitemia
vivax
malaria
consid
potenti
threaten
wide
varieti
commerci
avail
immunochromatograph
cassett
diagnosi
malaria
may
appli
compet
microscop
diagnosi
avail
though
simpl
often
effect
endem
set
diagnosi
less
sensit
expert
blood
plasma
glucos
mmoll
mgdl
sever
malari
anemia
hemoglobin
concentr
gdl
hematocrit
children
year
age
gdl
respect
adult
togeth
parasit
count
renal
impairmentacut
kidney
injuri
plasma
serum
creatinin
mgl
blood
urea
mmoll
jaundic
plasma
serum
bilirubin
mgdl
togeth
parasit
count
p
knowlesi
jaundic
parasitemia
pulmonari
edema
radiolog
confirm
oxygen
satur
room
air
respiratori
rate
often
chest
indraw
crepit
auscult
signific
bleed
includ
recurr
prolong
bleed
nose
gum
venipunctur
site
hematemesi
melena
shock
compens
shock
defin
capillari
refil
temperatur
gradient
leg
mid
proxim
limb
hypotens
decompens
shock
defin
systol
blood
pressur
mm
hg
children
mm
hg
adult
evid
impair
perfus
cool
peripheri
prolong
capillari
refil
hyperparasitemia
p
falciparum
parasitemia
p
knowlesi
parasitemia
parasitemia
limit
p
vivax
intramuscular
artemeth
patient
sever
malaria
manag
high
depend
unit
intens
care
unit
icu
alert
icu
renal
team
earli
rapid
deterior
median
time
hour
cerebr
malaria
mechan
ventil
need
protect
airway
acut
kidney
injuri
aki
well
document
ard
occur
later
median
time
day
even
patient
appear
improv
clinic
parasit
count
fall
detail
manag
patient
beyond
scope
review
howev
highlight
key
aspect
good
nurs
care
sick
patient
crucial
dilig
fluid
balanc
import
risk
fluid
overload
precipit
pulmonari
edema
increas
due
increas
pulmonari
capillari
leakag
patient
one
key
decis
clinician
make
whether
admit
patient
hospit
close
observ
nonimmun
malariainfect
patient
deterior
rapidli
parasit
count
increas
risk
develop
sever
diseas
death
uk
malaria
treatment
guidelin
recommend
admiss
falciparuminfect
patient
unless
care
specialist
unit
protocol
place
outpati
manag
rapid
initi
assess
follow
rapid
treatment
keyus
iv
give
day
quinin
may
given
day
qn
cinchon
common
bitter
tast
children
may
like
dox
contraind
year
unit
kingdom
year
unit
state
chloroquin
cq
resist
cq
total
dose
mgkg
hour
follow
local
recommend
reduc
dose
creatinin
clearanc
mlmin
avoid
sever
renal
diseas
cq
resist
cqr
act
atvpg
cqr
common
indonesia
papua
new
guinea
se
asia
foci
elsewher
first
line
treatment
chloroquin
altern
treatment
act
atvpg
first
line
treatment
act
asmq
al
dhapp
effect
hypoglycemia
may
recurr
quinin
treatment
otherwis
uncompl
diseas
malaria
second
third
trimest
treat
act
effect
safe
first
trimest
day
quinin
combin
clindamycin
recommend
recent
data
howev
show
similar
miscarriag
stillbirth
rate
quinin
act
treatment
first
trimest
sever
malaria
iv
drug
first
choic
trimest
use
dose
nonpregn
adult
primaquin
given
pregnant
woman
presumpt
antirelaps
therapi
part
primaquin
pose
complex
challeng
effect
treatment
p
vivax
p
oval
patient
diagnos
infect
consid
risk
multipl
recurr
attack
year
follow
primari
attack
frequenc
time
number
secondari
attack
vari
geograph
origin
infect
gener
may
occur
least
often
patient
renew
attack
debilit
potenti
danger
primari
attack
prescrib
part
prevent
relaps
strongli
recommend
base
good
evid
primaquin
regist
part
combin
chloroquin
radic
cure
vivax
malaria
dose
mg
base
daili
adult
day
commenc
concurr
chloroquin
therapi
within
week
complet
author
today
recommend
mg
daili
adult
day
high
efficaci
poor
efficaci
mg
dose
tropic
strain
p
vivax
taken
snack
meal
former
remark
safe
well
toler
nonpregn
patient
age
month
normal
dehydrogenas
activ
see
upcom
discuss
patient
prescrib
part
strictli
adher
may
nonetheless
suffer
relaps
vivax
oval
malaria
consequ
rel
poor
metabol
primaquin
activ
metabolit
cytochrom
isozym
isozym
highli
polymorph
extent
primaquin
metabol
may
impair
null
accord
allel
present
repeat
increas
dose
may
achiev
cure
former
latter
null
metabol
cure
latent
stage
malaria
ascertain
genotyp
patient
fail
part
undertaken
kept
dri
maintain
adequ
perfus
renal
function
inputoutput
chart
essenti
central
venouspressur
line
use
guid
fluid
manag
reserv
aggress
fluid
resuscit
patient
shock
still
exercis
caution
observ
care
respons
limit
number
fluid
challeng
seek
earli
icu
advic
regard
use
vasopressor
shock
sever
malaria
may
due
concurr
bacteri
infect
also
contribut
metabol
acidosi
develop
ard
take
blood
cultur
treat
promptli
broadspectrum
antibiot
aki
sever
malaria
hypercatabol
earli
renal
replac
treatment
may
need
convuls
manag
standard
way
look
correct
hypoglycemia
hypocalcemia
hyponatremia
hypoxia
hypoglycemia
may
occur
sever
malaria
particularli
quininetr
patient
even
recoveri
phase
regular
blood
glucos
concentr
fingerstick
necessari
everi
hour
routin
everi
hour
quinin
infus
time
patient
convuls
andor
reduc
level
conscious
treat
hypoglycemia
acut
dextros
prevent
episod
dextros
infus
part
fluid
mainten
full
blood
count
clot
biochemistri
includ
calcium
magnesium
phosphat
monitor
close
especi
aki
develop
daili
malaria
parasit
count
need
monitor
parasit
clearanc
blood
transfus
follow
local
icu
guidelin
platelet
transfus
indic
even
low
count
unless
activ
bleed
experi
pediatr
sever
malaria
come
subsaharan
africa
common
manifest
cerebr
malaria
sever
anemia
acidoticand
dehydrationdriven
respiratori
distress
convuls
hyperpyrexia
hypoglycemia
frequent
complic
clinic
cours
maitland
et
al
publish
guidelin
manag
nonimmun
children
pregnant
women
malaria
prone
sever
diseas
suffer
miscarriag
stillbirth
involv
obstetr
pediatr
team
earli
second
half
pregnanc
malaria
fulmin
diseas
associ
higher
mortal
nonpregn
women
two
featur
sever
malaria
stand
pregnanc
ard
relaps
treat
acut
attack
larg
studi
southeast
asia
howev
affirm
even
singl
attack
acut
vivax
falciparum
malaria
first
trimest
pregnanc
increas
odd
spontan
abort
stillbirth
low
birthweight
factor
compar
uninfect
women
provid
consid
strategi
spare
woman
stage
pregnanc
often
inevit
multipl
relaps
year
two
follow
primari
attack
one
option
exampl
may
monthli
presumpt
therapi
dihydroartemisininpiperaquin
least
month
follow
primari
attack
ie
elimin
blood
stage
present
emerg
month
follow
slowli
elimin
piperaquin
act
chemoprophylact
febril
ill
patient
histori
exposur
malaria
prompt
immedi
diagnost
workup
diagnosi
within
hour
possibl
malaria
presum
immedi
treat
five
speci
plasmodia
infect
human
potenti
danger
without
prompt
diagnosi
effect
treatment
patient
diagnos
p
vivax
p
oval
malaria
laboratori
evalu
defici
undertaken
prior
prescrib
primaquin
part
defici
ordinarili
silent
red
blood
cell
abnorm
render
patient
vulner
aha
caus
primaquin
drug
food
infect
differ
degre
defici
exist
sever
variant
caus
greater
primaquineinduc
aha
accordingli
daili
administ
primaquin
part
patient
may
lead
lifethreaten
aha
given
patient
without
ascertain
statu
screen
possibl
patient
may
administ
primaquin
clinic
supervis
daili
hemoglobin
measur
close
observ
darken
urin
color
onset
hemolysi
may
observ
within
day
therapi
safe
halt
moreov
part
prescrib
pregnant
risk
fetal
hemolysi
lactat
women
risk
hemolysi
infant
infant
month
age
safeti
data
diagnosi
defici
may
accomplish
qualit
screen
use
commerci
avail
laboratori
pointofcar
kit
qualit
screen
kit
type
suffer
drawback
insensit
normal
activ
although
pose
threat
hemizyg
male
homozyg
femal
xlink
trait
heterozyg
femal
may
screen
normal
yet
vulner
signific
aha
especi
sever
variant
like
mediterranean
femal
patient
examin
quantit
spectrophotometr
test
normal
activ
exclud
primaquin
part
earli
evid
safeti
regard
patient
show
selflimit
aha
sustain
daili
primaquin
therapi
studi
howev
conduct
otherwis
healthi
africanamerican
adult
male
volunt
rel
mild
african
avari
defici
today
understood
sever
variant
domin
area
p
vivax
common
ie
mediterranean
middl
east
asia
thu
defici
consid
seriou
threat
patient
unknown
statu
author
histor
recommend
regimen
mgkg
weekli
dose
week
part
patient
evid
safeti
regimen
african
subject
limit
weak
evid
efficaci
given
risk
signific
aha
dose
patient
receiv
close
monitor
patient
defici
medic
supervis
unknown
statu
pregnant
lactat
women
infant
null
metabol
receiv
primaquin
therapi
although
author
recommend
chloroquin
chemoprophylaxi
month
follow
primari
attack
p
vivax
malaria
random
control
trial
valid
safe
effect
make
recommend
matter
lack
evid
moreov
widespread
resist
chloroquin
speci
render
advic
even
less
use
issu
pregnant
women
especi
difficult
import
provid
wrongli
view
uncompl
vivax
malaria
benign
threaten
simpli
allow
pregnant
women
